GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Current Ratio

CPMV (Mosaic ImmunoEngineering) Current Ratio : 0.01 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mosaic ImmunoEngineering's current ratio for the quarter that ended in Sep. 2024 was 0.01.

Mosaic ImmunoEngineering has a current ratio of 0.01. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Mosaic ImmunoEngineering has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Mosaic ImmunoEngineering's Current Ratio or its related term are showing as below:

CPMV' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 5.67   Max: 80.71
Current: 0.01

During the past 13 years, Mosaic ImmunoEngineering's highest Current Ratio was 80.71. The lowest was 0.01. And the median was 5.67.

CPMV's Current Ratio is ranked worse than
99.47% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs CPMV: 0.01

Mosaic ImmunoEngineering Current Ratio Historical Data

The historical data trend for Mosaic ImmunoEngineering's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Current Ratio Chart

Mosaic ImmunoEngineering Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.85 4.29 0.12 0.07 0.04

Mosaic ImmunoEngineering Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.04 0.02 - 0.01

Competitive Comparison of Mosaic ImmunoEngineering's Current Ratio

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Current Ratio distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Current Ratio falls into.



Mosaic ImmunoEngineering Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Mosaic ImmunoEngineering's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=0.18/4.733
=0.04

Mosaic ImmunoEngineering's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=0.04/5.301
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Mosaic ImmunoEngineering Current Ratio Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering Business Description

Traded in Other Exchanges
N/A
Address
9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering Headlines

From GuruFocus

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019